Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 14/20 | 0.60 |
| ▸ | MAPK12 | P53778 | 14/20 | 0.60 |
| ▸ | MAPK11 | Q15759 | 14/20 | 0.60 |
| ▸ | RAF1 | P04049 | 11/20 | 0.60 |
| ▸ | BRAF | P15056 | 2/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.57 |
| ▸ | GCGR | P47871 | 4/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689783 | 0.88 | ALOX5 (0.62) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL2148412 | 0.83 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL16497630 | 0.82 | ALOX5 (0.81) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL12856388 | 0.79 | BRAF (0.90) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL14689935 | 0.77 | RAF1 (0.67) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL28403334 | 0.76 | MAPK13 (1.00) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL2649589 | 0.76 | MAPK13 (0.90) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL12461192 | 0.76 | RAF1 (0.62) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL16497633 | 0.75 | ALOX5 (0.82) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL2148438 | 0.75 | RAF1 (0.58) | MAPK14MAPK13MAPK12MAPK11RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| WO-2011085269-A1 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK14 193/4885MAPK13 142/4885MAPK12 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.